Ceftazidime-Avibactam Dosing for Neonates
For neonates, ceftazidime-avibactam should be dosed based on postnatal age and gestational age: 25 mg/kg/dose (ceftazidime 20 mg/kg and avibactam 5 mg/kg) IV every 8 hours for neonates ≤28 days with gestational age ≥31 weeks, and 37.5 mg/kg/dose (ceftazidime 30 mg/kg and avibactam 7.5 mg/kg) IV every 8 hours for infants >28 days to <3 months, administered over 2 hours. 1
Age-Based Dosing Algorithm
For Neonates ≤28 Days (Postnatal Age)
- Gestational age ≥31 weeks: 25 mg/kg/dose (ceftazidime 20 mg/kg + avibactam 5 mg/kg) IV every 8 hours 1
- Administered as 2-hour infusion 1
- This applies to both full-term and preterm neonates with corrected age ≤28 days 1
For Infants >28 Days to <3 Months
- Dose: 37.5 mg/kg/dose (ceftazidime 30 mg/kg + avibactam 7.5 mg/kg) IV every 8 hours 1
- Administered as 2-hour infusion 1
- This includes full-term infants with postnatal age >28 days and preterm infants with corrected age >28 days 1
For Infants 3 to <6 Months
- Dose: 50 mg/kg/dose (ceftazidime 40 mg/kg + avibactam 10 mg/kg) IV every 8 hours 1
- Maximum dose: 2000 mg ceftazidime/dose 2
Important Clinical Considerations
Renal function monitoring is critical, as both ceftazidime and avibactam are renally cleared, though specific dosing adjustments for neonates <2 years with renal impairment are not established 1. There is insufficient information to recommend dosing for neonates with renal impairment 1.
Recent pharmacokinetic data confirms these doses achieve appropriate plasma exposures in neonates and young infants that are comparable to approved doses in older children 3. A phase 2a study demonstrated that these weight-based regimens produced similar drug concentration-time profiles across neonatal age cohorts 3.
Safety Profile
The safety profile in neonates appears acceptable based on limited data, with adverse events consistent with the underlying critical illness rather than drug toxicity 3. In the phase 2a study, 50% of neonates had ≥1 adverse event, but no serious adverse events or deaths were treatment-related 3.
Clinical and microbiological response rates were favorable, with ≥80% of patients achieving favorable outcomes in the multiple-dose cohort 3. Case reports of extremely premature neonates treated with ceftazidime-avibactam for carbapenem-resistant Enterobacteriaceae infections have shown clinical cure, though outcomes can be complicated by underlying prematurity 4.
Administration Details
- Infusion time: Always administer over 2 hours 1
- Frequency: Every 8 hours for all neonatal age groups 1
- For complicated intra-abdominal infections: Combine with metronidazole 10 mg/kg IV every 8 hours 1
Critical Caveats
Guideline recommendations state "no recommendations available" for neonates, with the lowest age specified being 3 to <6 months 2. However, the FDA label now provides specific neonatal dosing based on recent pharmacokinetic studies 1, making these the most authoritative recommendations for clinical practice.
For neonates <31 weeks gestational age or those ≤28 days postnatal age, there is extremely limited data, and infectious disease consultation is strongly advised before use 3.